AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01669811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole (D961H) twice daily
Description: One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and in the evening
Study NCT03695705 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rifaximin 550 mg twice a day and Norfloxacin 400 mg once a day
Description: Patients on Rifaximin prophylaxis will be given 550 mg twice daily and on Norfloxacin prophylaxis will receive Norfloxacin 400 mg once daily for 6 months
Study NCT01020799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7268
Description: 15 mg, oral, twice daily (BID)
Study NCT01020799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 20 mg, oral, once daily (QD)
Study NCT01020799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo capsules
Description: Placebo capsules to match AZD7268
Study NCT01669811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole (D961H) once daily
Description: One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and one corresponding placebo capsule in the evening
Study NCT03363412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTFE-covered stent grafts
Description: Creation of a small diameter intrahepatic shunt between portal and hepatic veins.
Study NCT00654784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idebenone
Description: idebenone 450 mg/day (150 mg three times a day)
Study NCT00654784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02877355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: All subjects will receive 3 mg oral semaglutide for five days followed by 7 mg oral semaglutide for five days
Study NCT01345344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Practicing certain cognitive and behavioral pain self-management strategies such as relaxation and changing negative thoughts about pain.
Study NCT01345344 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Disease Education
Description: Providing information about fibromyalgia, including its potential causes and management approaches.
Study NCT02701686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: quit immediately (QI)
Description: advise to quit immediately using the AWARD model
Study NCT02701686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cut down to quit (CDTQ)
Description: advise to reduce cigarette consumption and quit eventally using the AWARD model
Study NCT01020799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Placebo capsules to match AZD7268
Study NCT02581111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Naloxone 8-mg IV bolus
Study NCT02581111 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Study NCT00568880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: bortezomib 1.0-1.3mg/m2 IV
Study NCT00568880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: hydroxychloroquine 200 mg pill
Study NCT01089582 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT03719326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist for oral use
Study NCT01020799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablets
Description: Placebo tablets to match encapsulated escitalopram
Study NCT01020799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Placebo tablets to match encapsulated escitalopram
Study NCT04478461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 monoclonal antibody
Description: The enrollment mainly depends on 3+3 principle. A total of 3 or 4 dose groups will be evaluated during the dose escalation period: 1, 3, 10 mg/kg, and maybe an additional fixed dose (e.g., to evaluate 200 mg or other fixed dose as RP2D). The drug is scheduled to be administrated Q3W
Study NCT03719326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-549
Description: IPI-549 is a phosphoinositide-3-kinase-gamma inhibitor for oral use
Study NCT03719326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: Doxil is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous (IV) use
Study NCT02782091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Errands Test (MET)
Description: 1 hour assessment in an unknown district with 2 independent raters.
Study NCT03719326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticle albumin-bound paclitaxel (NP)
Description: NP is a microtubule inhibitor for intravenous (IV) use
Study NCT01690169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-0987
Description: A single dose for oral administration, up to 7 dose levels will be investigated. If a non-tolerated dose level has been reached, the dose level will not be increased further.
Study NCT01690169 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A single dose of oral placebo administered.
Study NCT00620971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine (oral) 60 mg/m2, on days 1 and 8 every 3 weeks for 3 cycles
Study NCT00620971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 3 cycles
Study NCT00620971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 3 cycles
Study NCT03109119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: The patients in the group S will be exposed to routine concentrations of sevoflurane during anaesthesia.
Study NCT04063813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: 40 minute up trial
Study NCT04063813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: 40 minute down trial
Study NCT04063813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Two 20 minute up trials
Study NCT04063813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Two 20 min down trials
Study NCT04063813 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Sedentary trial
Study NCT04115163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT04115163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT02972996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blueberry
Description: 22 g freeze-dried whole blueberry powder
Study NCT02972996 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 22 g placebo blueberry powder
Study NCT02949206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will randomly receive matching placebo in all 3 Parts on day 1 administered via IV Route (for Part 1 and 2) and SC route (for Part 3).
Study NCT03109119 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Propofol
Description: These patients will be induced with propofol 1.5 mg / kg and maintained with propofol infusion.
Study NCT03447340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Canteen and Behavior intervention
Description: canteen intervention: (a) form and train a canteen improvement team; (b) train canteen staff on healthy cooking; (c) add healthy food and remove unhealthy food; (d) information and communication of canteen changes to employees; (e) monitoring of the interventions.~Behavioral : 16 core classes and 8 maintenance classes
Study NCT03447340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Canteen Only
Description: canteen intervention: (a) form and train a canteen improvement team; (b) train canteen staff on healthy cooking; (c) add healthy food and remove unhealthy food; (d) information and communication of canteen changes to employees; (e) monitoring of the interventions.
Study NCT00620971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
Study NCT00620971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine(IV) 1,100 mg/m2 on day 1 and d8 every 3 weeks for 6 cycles
Study NCT02349061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concomitant Medication
Description: Concomitant treatment (mycophenolate, azathioprine/6-mercaptopurine, methotrexate, hydroxychloroquine and/or chloroquine, oral corticosteroids, NSAIDs, antihypertensive medications, and topical medications) through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48.
Study NCT00620971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
Study NCT00620971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 6 cycles
Study NCT04118114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRL3-zumab
Description: IV administration every 2 weeks
Study NCT03374553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINI DO636
Description: MINIject 636 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant CS636 and a Delivery Tool.~The Delivery Tool is a single-use tool, designed for inserting the CS636 implant into the sub-scleral location through an ab-interno minimally-invasive approach.~For MINIject 636, there are 2 types of Delivery Tools available to implant and position the CS636 implant.~Both types of Delivery Tools are being studied in this amended study: Dual Operator Delivery Tool (DODT) and Single Operator Delivery Tool (SODT).~DODT is used in the first arm (cohort 1 - MINI DO636), SODT is used in the second arm (cohort 2 - MINI SO636).
Study NCT03374553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINI SO636
Description: MINIject 636 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant CS636 and a Delivery Tool.~The Delivery Tool is a single-use tool, designed for inserting the CS636 implant into the sub-scleral location through an ab-interno minimally-invasive approach.~For MINIject 636, there are 2 types of Delivery Tools available to implant and position the CS636 implant.~Both types of Delivery Tools are being studied in this amended study: Dual Operator Delivery Tool (DODT) and Single Operator Delivery Tool (SODT).~DODT is used in the first arm (cohort 1 - MINI DO636), SODT is used in the second arm (cohort 2 - MINI SO636).
Study NCT00484536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP323
Description: 250 mg capsules, 500 mg bid (1000 mg/day)
Study NCT00484536 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsules, once daily
Study NCT04325308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protein-enriched human milk diet
Description: 1.2 g of human-based protein will be added to each 100 ml of human milk administered
Study NCT04325308 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual human milk diet
Description: Human-based protein will not be added to the human milk administered.
Study NCT00484536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP323
Description: 250 mg Capsules, 500 mg, once daily
Study NCT04215523 — intervention group
Intervention type: DRUG
Intervention: Dapagliflozin
Description: Dapagliflozin dispensing claim for any dose is exposure
Study NCT04215523 — intervention group
Intervention type: DRUG
Intervention: DPP-4 inhibitor
Description: DPP4 inhibitor dispensing claim for any dose is reference
Study NCT02176395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danhong injection
Description: 40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
Study NCT00316719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAM group
Description: Subjects took one LAM 100mg tablet orally once daily and one ADV placebo tablet orally once daily.
Study NCT00316719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADV group
Description: Subjects took one ADV 10mg tablet orally once daily and one LAM placebo tablet orally once daily.
Study NCT03493399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interference
Description: The principle of interference-based techniques is to move the resources allocated to the elaboration of intrusive desire thoughts to a competing task (e.g., clay modelling, competitive mental imagery, Tetris) in order to monopolize the resources underlying craving, thus preventing its elaboration and reducing its vividness and overwhelming nature. Several studies (Andrade, Pears, May, \& Kavanagh, 2012; May, Andrade, Panabokke, \& Kavanagh, 2010; Skorka-Brown, Andrade, Whalley, \& May, 2015) have shown the efficacy of such techniques to reduce substance-related craving. Yet, data obtained on clinical samples remain scarce.~Due to the flexibility of the single case design towards each participant, the list of interference-based techniques that will be used in this study cannot be exhaustive. However, the following will be proposed to participants: Tetris (smartphone version), manipulation of a bunch of keys, manipulation of a fidget, mental imagery, reading and memorizing a text.
Study NCT01559467 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cardiovascular Magnetic Resonance Imaging
Description: Routine clinical care plus cardiovascular magnetic resonance imaging early in the diagnostic process
Study NCT01814982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-17299425
Description: JNJ-17299425 will be administered at a starting dose of 1 milligram (10 milliliter of a 0.1 mg/ml solution) as intravenous bolus injection over 2 minutes in central vein.
Study NCT02750969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lidoderm patch (Lidocaine 5% patch)
Description: The investigator will attach the patches on the patient's back for 12 consecutive hours.~tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch
Study NCT02750969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tegaderm patch. (neutral patch, containing no drug)
Description: The investigator will attach the patches on the patient's back for 12 consecutive hours.~tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch
Study NCT02750969 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood test- serum lidocain levels
Description: each participant will undergo blood test. the participant's group that start the trial with the lidoderm patch and later will use the tegaderm patch will have 2 blood tests for werum lidocain level test. the group taht start the trial with the tegaderm patch and later the lidoderm patch will have only one blood test measuring lidocaine serum level.~the tubes containing the serum will be shipped abroad via an international medical cargo company for lidocaine levels tests.
Study NCT02750969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hearing tests
Description: each participant that have not done hearing test in the last 1 year previous to the trial will have one in the first day of the trial.
Study NCT01067430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib
Description: Film coated tablet, 90 mg taken once a day for 14 days
Study NCT01067430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Enteric coated tablet 50 mg given three times a day for 14 days
Study NCT02031406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-discharge counseling on medication adherence & literacy
Study NCT01542970 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Olive oil
Study NCT01542970 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olive oil
Study NCT01542970 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: Omega-3 PUFA treatment comprises of maternal supplementation of 3 capsules of Pikasol® (1g capsules containing 640 mg ω-3 PUFA) 2 times daily during pregnancy and lactation.
Study NCT01542970 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Refined coconut and peanut oil without L. reuteri
Description: 2x20 drops daily to the mother from gw 20 and from birth to the child during the first year of life
Study NCT01542970 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Refined coconut and peanut oil without L. reuteri
Description: 2x20 drops daily to the mother from gw 20 and from birth to the child during the first year of life
Study NCT01542970 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. reuteri
Description: The L. reuteri supplementation comprises of L. reuteri suspension 109 colony forming units (CFU) in oil (refined coconut and peanut oil) (20 droplets x 2 daily) to the mothers during pregnancy and 108 CFU (5 droplets x 1) to the children during the first years of life
Study NCT00862940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 10 mg tablets twice daily
Study NCT00862940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets twice daily
Study NCT01559467 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Computed Tomography Angiography
Description: Routine clinical care plus computed tomography angiography early in the diagnostic process
Study NCT04336306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality-based therapy (VRBT)
Description: The warm-up was performed using the Just Dance 2015 game, in a sequence previously defined in a pilot study, aiming to increase HR progressively. A multimedia projector (Epson Power Life, H309A, China) connected to a console (Xbox One KinectTM, Microsoft, Redmond, WA) was used to project the game onto a white wall.The conditioning phase was performed using the Shape Up exercise game, in which patients perform exercises following a virtual therapist.
Study NCT03308201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay022+exemestane
Description: Part one: Hemay022 tablets will be taken orally once daily in doses of 200mg, 300mg,400mg or 500mg for 28 days in combination with exemestane.~Part two: Hemay022 tablets combination with exemestane.
Study NCT03308201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay022+letrozole
Description: Part two: Hemay022 combination with letrozole.
Study NCT03308201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay022+ fulvestrant
Description: Part two: Hemay022 combination with fulvestrant.
Study NCT03240484 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: X-Ray Imaging
Description: X-Ray imaging in the following positions: Lateral standing, lateral seated, standard standing AP pelvis and AP pelvis lying down.
Study NCT02648945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: first, Verbal Memory task was completed by each participant. Participant then started walking on the treadmill at either a speed of 3.0 mph (4.8 km/h) for sedentary individuals or 3.5 mph (5.6 km/h) for active individuals with grade 0% (Hanson, 1984). This was followed by an increase in grade of 2% for every 2 mins with the speed remaining constant until targeted HR was reached. A heart rate (HR) monitor (POLAR®) was used to measure HR throughout the test and rating of perceived exertion (RPE) was done at the end of every 2 min stage. Exercise was stopped as soon as participant reaches targeted HR or requests to stop because of fatigue or any discomfort. Participant was then given time to cool down until HR reached or fell below 120 bpm and was allowed to take a break for approximately 1 min before proceeding with the second set of Verbal Memory Task. Upon completing the memory test, the participant was allowed to leave
Study NCT03240484 — intervention group
Intervention type: OTHER
Intervention: Gait Analysis
Description: Certain patients may be asked to participate in a motion analysis procedure at the Human Movement Laboratory at the University of Ottawa. This procedure takes approximately 1.5 hours and you will only be asked to participate in the motion analysis procedure once. Participants will change into a custom-designed tight body suit, which has reflective markers on its surface for infrared video capture. Participants will then have pairs of surface electromyography (EMG) electrodes placed on certain areas of the skin on the legs and on the back. Wearing the EMG electrodes and marker suit, participants will perform 5 trials of walking on a level walkway, walking up and down a 3-step staircase, sitting from a standing position, and standing from a seated position.